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Introduction
Cholecystokinin (CCK) belongs to a group of endogenous molecules known as brain-gut neuropeptides and functions as a neu-
ropeptide as well as a gut hormone. It remains unclear whether genetic variation of the CCK receptor plays a role in irritable 
bowel syndrome (IBS). The aim of this study was to determine and compare the allele and genotype frequencies of the CCK1 
receptor polymorphisms between healthy controls and patients with IBS. 
Methods
Genotyping of 80 patients with IBS (who met the Rome III criteria) and 76 healthy controls was performed. We performed 
PCR amplification for the CCK1 receptor intron 1 779 T ＞C and Exon 1 G ＞A. We confirmed polymorphisms by direct se-
quencing method.
Results
There was a significantly different trend for genotypic distributions of the CCK1 receptor polymorphism between patients with 
IBS and healthy controls (p for trend = 0.048). The CCK1 receptor intron 1 779 T ＞C polymorphic type was more common 
in patients with ‘IBS-constipation predominant (IBS-C) and IBS-mixed (IBS-M) forms’ (19/31, 61.3%) than healthy controls 
32/76, 42.1% adjusted odd ratio 2.43, 95% Confidence interval 1.01-5.86). The genotypic distributions of the CCK1 receptor 
exon 1 polymorphism were not significantly different between the two groups (p for trend = 0.223).
Conclusions
CCK1 receptor polymorphisms were associated with IBS. In particular, the CCK1 receptor intron 1 779 T ＞C polymorphic type 
was associated with ‘IBS-C and IBS-M’. Further studies are needed in larger number of patients with an even distribution of 
IBS subtypes. 
(J Neurogastroenterol Motil 2010;16:71-76)
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Introduction
Irritable bowel syndrome (IBS) is characterized by the pres-
ence of abdominal discomfort or pain associated with disturbed 
defecation. IBS is important because of its high prevalence, sub-
stantial morbidity, and enormous cost. In clinical practice of gas-
troenterology, more than one third of the patients have functional 
gastrointestinal disorders, and IBS is the most common 
diagnosis.
1 However, the etiology and physiology of IBS are not 
fully understood. A number of different mechanisms have been 
implicated in the pathogenesis of IBS including abnormal mo-
tility, visceral hypersensitivity, low-grade inflammation, and 
stress.
2 No single pathophysiological mechanism explains the 
clinical manifestation of IBS entirely. Current evidence suggests 
that an altered brain-gut axis is the key mechanism associated 
with disordered motility, visceral hypersensitivity, and autonomic 
dysfunction. Regulation of these connections occurs via numer-
ous neurotransmitters such as cholecystokinin (CCK), vasoactive 
intestinal peptide (VIP), substance P, serotonin, and cortico-
trophin releasing hormone (CRH).
3 Cholecystokinin (CCK) is a 
neuropeptide released by endocrine I cells within the duodenal 
and jejunal mucosa in response to a variety of nutrients, notably 
the digestion products of fat, and its secretion is associated with 
contraction of the gallbladder, pancreas enzyme secretion, and in-
hibition of gastric emptying.
4 Two receptor subtypes of CCK 
have been identified, CCK1 and CCK2, which were initially clas-
sified pharmacologically on the basis of their affinity for the en-
dogenous peptides CCK and gastrin and several selective 
non-peptide antagonists.
5 Both CCK1 and CCK2 belong to a sin-
gle family of G-coupled receptors (GPCRs): the CCK1 is pre-
dominantly located in the gastrointestinal (GI) track (previously 
called CCKA, where A = alimentary), whereas the CCK2 re-
ceptor is distributed widely throughout the central nervous sys-
tem (CNS) (previously called CCKB, where B = brain).
6 
Blocking of the CCK1 receptors in the GI tract has been pro-
posed as a novel approach to stimulate gut motility and to change 
colonic transit time in patients with constipation-predominant 
functional bowel disorders.
7 CCK1 receptor polymorphism in 
IBS patients with constipation has been associated with slower 
gastric emptying.
7 However, it remains unclear whether genetic 
variation of the CCK receptor plays a role in the pathogenesis of 
IBS. Thus, the aim of this study was to determine and compare 
the allele and genotype frequencies for the CCK1 receptor poly-
morphism between healthy controls and patients with IBS. 
Materials and Methods
1. Subjects
This was a case-control study. The subjects in this study were 
recruited between March 2007 and February 2008. Eighty out-
patients with IBS, who were referred to a tertiary hospital and 76 
healthy controls, who visited the health promotion center for a 
routine checkup were enrolled. The subjects with IBS were diag-
nosed according to the Rome III criteria.
8 Healthy controls had 
no prior history of disease or symptoms related to the gastro-
intestinal system in the study. IBS subjects were excluded if they 
had an unstable medical disorder, another gastrointestinal dis-
order, a major psychiatric disorder, or a history of substance 
abuse within the previous two years. 
This study was approved by the institutional review board of 
the Chonnam National University Hospital, Gwangju, Korea. 
All subjects were provided with written information on the proj-
ect, and informed consent was obtained as well.
2. Genotyping
Venous blood drawn from a forearm vein was stored at 
-70
oC. DNA was extracted from whole blood by the alkaline lysis 
method using the QIAamp DNA Midi Kit (Qiagen Inc., 
Valencia, CA, USA). We examined the DNA for the CCK1 re-
ceptor polymorphisms in intron 1 and exon 1. We performed 
PCR amplification using GeneAmp 2700 for the CCK1 receptor 
intron 1 779 T ＞ C and Exon 1 G ＞ A. The forward primers 
and reverse primers used for the CCK1 receptor intron 1 779 T
＞ C were 5’-CTG TTC ACT TGA GGA GCT TTG-3’ and 
5’-TTA GAA ACT GAC CTC CAA CAT GG-3’. The for-
ward primers and reverse primers used for Exon 1 G ＞ A were 
5’-ATG AGC CGG GAG TGA GCA AT-3’ and 5’-GCC 
TTT GCT GAT TTC TCC CAC-3’ (GeneBank accession 
number #U23427). Amplification of intron 1 779 T ＞ C and 
Exon 1 G ＞ A was performed in a 25 reaction volume contain-
ing 100 ng of genomic DNA, Tris-HCl (pH 9.0), (NH4)2SO4 , 
20 mM MgCl2, PCR enhancers in reaction buffer 2.5 μL, DW 
16.5 μL, and Exprime Taq polymerase (Genet BIO Teageon, 
Korea) 0.5 μL. DNA was predenatured at 94
oC for 10 min, and 
subjected to 35 cycles of 30 sec of denaturation at 94
oC, 1 min of 
annealing at 60
oC, 30 sec of extension at 72
oC, and 10 min of fi-
nal extension at 72
oC (Table 1). The amplification products were 
resolved by electrophoresis on 1.8% SeaKem LE agarose CCK1 Receptor Gene Polymorphisms in IBS
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Table 1. Nucleotide Sequences for Assay Primer and PCR Condition for Polymorphisms in the CCK1 Receptor Polymorphisms
Intron 1 779 Exon 1
Primer
    Forward primer sequence 5’-3’ CTGTTCACTTGAGGAGCTTTG ATGAGCGGGAGTGAGCAAT
    Reverse primer sequence 5’-3’ TTAGAAGCTGACCTCCAACATGG GCCTTTGCTGATTTCTCCCAC
PCR condition
    Predenaturing At 94
oC for 10 min At 94
oC for 10 min
    Denaturing At 94
oC for 30 sec At 94
oC for 30 sec
    Annealing At 60
oC for 60 sec At 60
oC for 60 sec
    Extension At 72
oC for 30 sec At 72
oC for 30 sec
    Final extension At 72
oC for 10 min At 72
oC for 10 min
Product size 240 bp 744 bp
Table 2. Clinical Characteristics of the IBS Patients and Healthy Controls
Healthy controls (n = 76) IBS patients (n = 80) IBS-D patients (n = 49) IBS-C and IBS-M patients (n = 31)
Female, n (%) 44 (57.9) 50 (62.5) 28 (57.1) 22 (71.0)
Age (yr), mean ± SD 40.2 ± 12.8 37.9 ± 11.9 38.3 ± 12.8 37.4 ± 10.6
IBS, irritable bowel syndrome; IBS-D, IBS with diarrhea-predominant pattern; IBS-C, IBS with constipation-predominant bowel pattern; IBS-M, IBS with mixed 
pattern.
(Cambrex Bio Science Rockland, Inc., Rockland, ME, USA) 
next to a DNA molecular weight standard marker 100 bp ladder 
(TAKARA BIO Inc., Otsu, Shiga, Japan) and visualized with 
ethidium bromide staining. We confirmed polymorphisms by di-
rect sequencing with ABI version 3.1 Sequence Analysis 
software. 
3. Statistical methods
Statistical analysis was performed using the SPSS for 
Windows version 17.0 (SPSS Inc., Chicago, IL, USA). The 
statistical significance of the differences between the subjects with 
IBS and healthy controls was estimated by logistic regression 
analysis. Adjusted odds ratios (aORs) were calculated with a lo-
gistic regression model that were controlled by gender and age 
with 95% confidence intervals (CI). A p ＜ 0.05 was considered 
as the level of significance. Mann-Whitney U test were used to 
determine whether there were difference in the demographic data 
of the IBS patients and healthy controls. Subjects with wild type 
genotypes (intron 779 TT, exon 1 GG) were considered to be at 
baseline risk. The expected frequency of healthy control’s geno-
types was assessed by Hardy-Weinberg equilibrium test.
9 
Linkage disequilibrium was calculated using the SNP Analyzer 
program (Istech Ltd., Goyang-si, Korea). 
Results
1. Clinical characteristics of the study population
In the IBS patients, the median age was 35 years (range 
22-67 years) and female patients comprised 62.5%. In healthy 
controls, the median age was 38 years (range 22-69 years) and fe-
male subjects comprised 57.9%. There were no statistical differ-
ence between the IBS patients and healthy controls in the age or 
sex (p ＞ 0.05) (Table 2). Forty-nine of the IBS subjects had a 
diarrhea-predominant bowel pattern (IBS-D), 15 had a con-
stipation-predominant bowel pattern (IBS-C), and 16 had a 
mixed pattern (IBS-M). 
2. CCK1 receptor intron 1 779 T > C and exon 1 G > A 
polymorphism in the IBS patients and in healthy controls
The distribution of the CCK1 receptor intron 779 and exon 1 
polymorphisms in healthy controls was in Hardy-Weinberg 
equilibrium (Intron 779; p = 0.505, exon 1; p = 0.496). 
1) CCK1 receptor intron 1 779 T ＞ C polymorphism 
in the IBS patients and in healthy controls
Table 3 shows the genotype distributions and allele frequen-
cies of the CCK1 receptor intron 1 779 T ＞ C polymorphism in 
the IBS patients and healthy controls. There was a significantly Seon-Young Park, et al
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Table 3. Genotype Frequency for CCK1 Receptor Intron 1 779 T ＞ C in the IBS Patients and in Healthy Controls
Genotype TT TC CC C carrier
Total, n (%) 80 (51.3)    65 (41.7)    11 (7.0)    76 (48.7)
Healthy controls, n (%) 44 (57.9)    29 (38.2)      3 (3.9)    32 (42.1)
IBS, n (%) 36 (45.0)    36 (45.0)      8 (10.0)    44 (55.0)
    aOR (95% CI)   1 (Reference) 1.58 (0.81-3.09) 3.46 (0.84-14.25) 1.75 (0.92-3.34)
    p-value
a       0.177         0.086        0.870
IBS-D, n (%) 24 (49.0)    20 (40.8)      5 (10.2)    25 (51.0)
    aOR (95% CI)   1 (Reference) 1.31 (0.61-2.80) 3.37 (0.71-15.85) 1.48 (0.71-3.07)
    p-value
b       0.484         0.134        0.320
IBS-C and IBS-M, n (%) 12 (38.7)    16 (51.6)      3 (9.7)    19 (61.3)
    aOR (95% CI)   1 (Reference) 2.29 (0.92-5.70) 3.58 (0.61-20.97) 2.43 (1.01-5.86)
    p-value
c       0.082         0.176        0.048
ap for trend = 0.048, 
bp for trend = 0.151, 
cp for trend = 0.045.
CCK, cholecystokinin; IBS, irritable bowel syndrome; IBS, irritable bowel syndrome; IBS-D, IBS with diarrhea-predominant pattern; IBS-C, IBS with 
constipation-predominant bowel pattern; IBS-M, IBS with mixed pattern; OR, odds ratio; CI, confidence interval.
OR and 95% CI were estimated using multiple logistic regression and adjusted for sex and age.
Table 4. Genotype Frequency for CCK1 Receptor Exon 1 G ＞ A in the IBS Patients and in Healthy Controls
Genotype GG GA AA A carrier
Total, n (%) 129 (82.2)    27 (17.2) 1 (0.6)    28 (17.8)
Healthy controls, n (%)   65 (85.5)    11 (14.5) 0 (0.0)    11 (14.5)
IBS, n (%)   63 (78.8)    16 (20.0) 1 (1.2)          17
    aOR (95% CI)     1 (Reference) 1.50 (0.64-3.50)     - 1.59 (0.69-3.69)
    p-value
a       0.348  0.999         0.28
IBS-D, n (%)   38 (77.6)    11 (22.4) 0 (0.0)    11 (22.4)
    aOR (95% CI)     1 (Reference) 1.76 (0.69-4.44)     - 1.75 (0.29-4.44)
    p-value
b       0.237     -         0.237
IBS-C and IBS-M, n (%)   25 (80.6)      5 (16.1) 1 (3.2)      6 (19.3)
    aOR (95% CI)     1 (Reference) 1.28 (0.39-4.15)     - 1.55 (0.51-4.76)
    p-value
c       0.684  0.999         0.444
ap for trend = 0.223, 
bp for trend = 0.237, 
cp for trend = 0.269.
CCK, cholecystokinin; IBS, irritable bowel syndrome; IBS-D, IBS with diarrhea-predominant pattern; IBS-C, IBS with constipation-predominant bowel pattern; 
IBS-M, IBS with mixed pattern; OR, odds ratio; CI, confidence interval.
OR and 95% CI were estimated using multiple logistic regression and adjusted for sex and age.
different trend for genotypic distributions of CCK1 receptor in-
tron 1 779 T ＞ C polymorphism between the IBS patients and 
healthy controls (p for trend = 0.048). However, no significant 
difference was observed in C carrier between the two groups (p
= 0.870). The TC genotype was 45% (36/80) in IBS patients 
and 38.2% (29/76) in controls (p = 0.177, aOR 1.58, 95% CI 
0.81-3.09). The CC genotype was 10.0% (8/80) in IBS patients 
and 3.9% (3/76) in healthy control (p = 0.086, aOR 3.46, 95% 
CI 0.84-14.25). 
The CCK1 receptor intron 1 779 T ＞ C polymorphic type 
(TC genotype and CC genotype) was more common in patients 
with ‘Non IBS-D (IBS-C and IBS-M)’ (19/31, 61.3%) than it 
was in healthy controls (32/76, 42.1%, aOR 2.43 95% CI 
1.01-5.86) (Table 3).
2) CCK1 receptor exon 1 G>A  p o l y m o r p h i s m  i n  
the IBS patients and in healthy controls
The genotypic distributions (p for trend = 0.223) and A car-
rier frequencies (p = 0.28) of the CCK1 receptor exon 1 poly-
morphism were not significantly different between the two 
groups (Table 4).
Discussion
CCK belongs to the group of endogenous molecules known CCK1 Receptor Gene Polymorphisms in IBS
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as ‘brain-gut neuropeptides’ and, due to its anatomical location, it 
functions as a neuropeptide as well as a gut hormone. CCK is also 
found in the nerves of the circular muscle layer of the colon, to 
some extent in the ileum, and it is abundant in the celiac plexus 
and vagus nerves.
10 Due to these multiple anatomical locations it 
is not surprising that CCK has been implicated in different phys-
iological functions: gallbladder contraction and pancreatic en-
zyme secretion, as well as motor and sensory functions at various 
levels of the gastrointestinal tract such as gastric emptying and 
colonic motility.
11 The role of CCK was first reported by Harvey 
et al. who have observed CCK to cause an abnormal increase in 
colonic motility in patients with IBS.
12 Further studies have 
shown that the release of CCK, induced by a fatty meal, acts as a 
mediator of the gastrocolonic response.
13 CCK infusion appears 
to unmask intestinal dysmotility in patients with IBS.
14 Intraduo-
denal lipids increased visceral sensitivity in both IBS-D and 
IBS-C patients suggesting a role for CCK at the neuronal level. 
In patients with functional abdominal pain syndromes, infusion 
of CCK8 correlate with significantly higher pain scores compared 
to control subjects.
15 Therefore, the promising potential use of 
CCK1 antagonists for the treatment of a variety of functional gas-
trointestinal disorders including IBS will be expected.
Recent reports in human subjects have shown an association 
between CCK1 receptor gene polymorphism and schizophrenia,
16 
alcohol dependence,
17 panic disorder,
18 gallstone disease,
19 and 
postprandial dyspepsia.
20 However, there have been no reports 
on the association between the CCK1 receptor polymorphism and 
IBS. The results of present study suggest that the CCK1 receptor 
intron 1 779 T ＞ C polymorphism may be functionally im-
portant, since the genotypic distribution of the CCK1 receptor in-
tron 1 779 T ＞ C polymorphism in IBS patients had a sig-
nificantly different trend compared to that in healthy controls (p 
for trend = 0.048). Moreover, the findings of this study showed 
that the CCK1 receptor intron 1 779 T ＞ C polymorphic type 
(TC genotype and CC genotype) was associated with an in-
creased odds ratio for ‘non-IBS-D (IBS-C and IBS-M)’ (aOR 
2.43, 95% CI 1.01-5.86). However, we did not find any associa-
tion between the CCK1 receptor intron 1 779 T ＞ C poly-
morphic type and patients with IBS-D, implying that the genetic 
variation was only associated with IBS patients of ‘non IBS-D’ 
type from our study. In a study of Caucasian patients, the CCK1 
receptor intron 1 779 T ＞ C polymorphism in patients with 
IBS-C, was associated with slower gastric emptying. This sug-
gested that, compared to the 779 T variant, the 779 C sub-
stitution resulted in an increased response to endogenous CCK 
(like CCK agonist), which was followed by delaying gastric 
emptying.
7 From the viewpoint of sensory functions at various 
levels of the gastrointestinal tract, our results are consistent with 
the original hypothesis that suggested that the CCK1 receptor in-
tron 1 779 T ＞ C polymorphic type might have an increased re-
sponse to endogenous CCK and be associated with visceral 
hypersensitivity. However, from the viewpoint of colon motility, 
present study showed an opposite trend to our expectation that 
the CCK1 779 C substitution would be related with accelerating 
colon transit time, like CCK agonist. Therefore, characterization 
of the CCK1 receptor polymorphism and its clinical significance 
require further study.
The limitations of the present study include the following. 
First, this study was limited by the small sample size and uneven 
distribution of IBS subtypes. Second, present study did not show 
clinical significance for the CCK1 receptor polymorphism in re-
gard to visceral hypersensitivity and colon motility. Further stud-
ies are needed with larger patient samples with an even dis-
tribution of IBS subtypes. However, our findings suggest that 
the CCK1 intron 1 779 T ＞ C polymorphism might have a sig-
nificant association with IBS.
The presence of CCK1 receptor polymorphisms may indeed 
provide new opportunities for predicting how patients will re-
spond to a particular treatment according to their genetic profile, 
and therefore may have an impact on current management 
strategies. Therefore, pharmacogenomic studies on CCK1 re-
ceptor polymorphisms and the CCK antagonist might be of sig-
nificant interest and potential clinical relevance.
In summary, we have shown that CCK1 receptor poly-
morphisms are associated with IBS. In particular, the CCK1 re-
ceptor intron 1 779 T ＞ C polymorphic type was associated with 
non-IBS-D. However, further studies are needed in larger pa-
tient samples with an even distribution of IBS subtypes. In addi-
tion, further studies for the characterization of CCK1 receptor 
polymorphisms and understanding of its clinical significance by 
associations with clinical outcomes are also needed. 
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